{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:03:26Z","timestamp":1748059406679,"version":"3.41.0"},"reference-count":31,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Research in recent decades has shown a steady increase in the average life expectancy of humans, and women in particular. Any epithelial tissue reacts to changes in the surrounding hormonal environment in a similar way, but none of them can compare with the epithelium of the vaginal vault and cervix in terms of the speed and clarity of reaction to hormones, primarily sex steroids. The urogenital tract is especially sensitive to a decrease in estrogen levels, and about half of all women, both in reproductive age and during hormonal changes, may experience symptoms associated with vulvovaginal atrophy, affecting sexual health and quality of life. Estriol is the main estrogen that specifically addresses problems caused by estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary disorders, moderate urinary incontinence, as well as recurrent vulvovaginitis and cystitis. According to international and Russian clinical guidelines, the prescription of 0.5 mg is pathogenetically justified with a high level of persuasiveness and reliability. Vulvovaginal dystrophy in women of different ages is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.<\/jats:p>","DOI":"10.14341\/probl13575","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:37:53Z","timestamp":1747841873000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenetically justified use in real clinical practice of vaginal estriol 0.5 mg in women of different ages"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-0020","authenticated-orcid":true,"given":"E. N.","family":"Andreeva","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-0254","authenticated-orcid":true,"given":"E. V.","family":"Sheremetyeva","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre; Russian University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F.","family":"Vesnina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-6318","authenticated-orcid":true,"given":"Z. A.","family":"Uzhegova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279\u2013285. doi: https:\/\/doi.org\/10.1080\/13697130902814751","DOI":"10.1080\/13697130902814751"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2019.03.013","DOI":"10.1016\/j.maturitas.2019.03.013"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric J Int Menopause Soc. 2018;21(3):286\u2013291","DOI":"10.1080\/13697137.2018.1446930"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Andreeva EN, Sheremetyeva EV. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. Problems of Endocrinology. 2022;68(6):157-163. (In Russ.). doi: https:\/\/doi.org\/10.14341\/probl13198","DOI":"10.14341\/probl13198"},{"key":"ref5","unstructured":"\u0410\u043f\u043e\u043b\u0438\u0445\u0438\u043d\u0430 \u0418.\u0410., \u0413\u043e\u0440\u0431\u0443\u043d\u043e\u0432\u0430 \u0415.\u0410. \u041a\u043b\u0438\u043d\u0438\u043a\u043e-\u043c\u043e\u0440\u0444\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0430\u0441\u043f\u0435\u043a\u0442\u044b \u0432\u0443\u043b\u044c\u0432\u043e\u0432\u0430\u0433\u0438\u043d\u0430\u043b\u044c\u043d\u043e\u0439 \u0430\u0442\u0440\u043e\u0444\u0438\u0438. \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0439 c\u043e\u0432\u0435\u0442. 2014; 9: 110-7."},{"key":"ref6","unstructured":"Bleibel B, Nguyen H. Vaginal Atrophy. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Crandall CJ. Treatment of Vulvovaginal Atrophy. JAMA. 2019;322(19):1910-1911. doi: https:\/\/doi.org\/10.1001\/jama.2019.15100","DOI":"10.1001\/jama.2019.15100"},{"key":"ref8","unstructured":"Klinicheskie rekomendacii, proekt, Amenoreya i olinomenoreya, 2024, MZ RF (In Russ.). https:\/\/roag-portal.ru\/projects_gynecology"},{"key":"ref9","unstructured":"Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchin, . \u2014 Moskva, 2021. (In Russ.)."},{"key":"ref10","unstructured":"Registr lekarstvennyh sredstv Rossii (In Russ.). https:\/\/www.rlsnet.ru\/drugs\/ovestin-67#sposob-primeneniia-i-dozy"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus. 2020;12(4):e7586. doi: https:\/\/doi.org\/10.7759\/cureus.7586","DOI":"10.7759\/cureus.7586"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi: https:\/\/doi.org\/10.1097\/GME.0000000000001609","DOI":"10.1097\/GME.0000000000001609"},{"key":"ref13","unstructured":"Apolihina IA, Yureneva SV, Malyshkina DA. Genitourinarnyj menopauzal\u2019nyj sindrom: sovremennye podhody k diagnostike i lecheniyu. Akusherstvo i ginekologiya. 2020;12:4-8 (In Russ.)."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Khan IU, Serra CA, Anton N, Er-Rafik M, Blanck C, et al. Microfluidic conceived Trojan microcarriers for oral delivery of nanoparticles. Int J Pharm. 2015;493(1-2):7-15. doi: https:\/\/doi.org\/10.1016\/j.ijpharm.2015.06.028","DOI":"10.1016\/j.ijpharm.2015.06.028"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4(1):1-25. doi: https:\/\/doi.org\/10.3390\/pharmaceutics4010001","DOI":"10.3390\/pharmaceutics4010001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li X, Anton N, Ta TM, Zhao M, Messaddeq N, Vandamme TF. Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery. Int J Nanomedicine. 2011;6:1313-1325. doi: https:\/\/doi.org\/10.2147\/IJN.S20353","DOI":"10.2147\/IJN.S20353"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Comini ACM, Carvalho BM, Moreira MJB, Reis PCA, Colapietro L, et al. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2023;23(8):835-846. doi: https:\/\/doi.org\/10.1016\/j.clbc.2023.08.003","DOI":"10.1016\/j.clbc.2023.08.003"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"L\u00e1zaro-Carrasco de la Fuente J, Cuerva Gonz\u00e1lez M, Gonz\u00e1lez Rodr\u00edguez S, Delgado Mar\u00edn JL, Cuevas Castillo C, Nieto Magro C. Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy. J Menopausal Med. 2022;28(2):60-69. doi: https:\/\/doi.org\/10.6118\/jmm.21038","DOI":"10.6118\/jmm.21038"},{"key":"ref19","unstructured":"Nederzhanie mochi u vzroslyh. Klinicheskie rekomendacii. \u2014 MZ RF. \u2014 Moskva, 2024 (In Russ.)."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause (New York, NY). 2017;24(4):452\u2013461","DOI":"10.1097\/GME.0000000000000768"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Vetuschi A, D\u2019Alfonso A, Sferra R, et al. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse. Eur J Histochem. 2016;60(1):33-38","DOI":"10.4081\/ejh.2016.2604"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821-835. doi: https:\/\/doi.org\/10.1080\/14656566.2019.1574752","DOI":"10.1080\/14656566.2019.1574752"},{"key":"ref23","unstructured":"Vzaimozamenyaemye lekarstvennye preparaty (p. 4 ch. 4 st. 3 Federal\u2019nogo zakona ot 27.12.2019 \u2116 475-FZ, p. 8 postanovleniya Pravitel\u2019stva ot 05.09.2020 \u2116 1360) (In Russ.)."},{"key":"ref24","unstructured":"Nederzhanie mochi. Klinicheskie rekomendacii. \u2014 MZ RF. \u2014 Moskva, 2020 (In Russ.)."},{"key":"ref25","unstructured":"Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchin, . \u2014 Moskva, 2024. (In Russ.)."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi: https:\/\/doi.org\/10.1016\/S2213-8587(19)30189-5","DOI":"10.1016\/S2213-8587(19)30189-5"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(11). doi: https:\/\/doi.org\/10.1002\/14651858.CD001500.pub3","DOI":"10.1002\/14651858.CD001500.pub3"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rueda C, Osorio AM, Avellaneda AC, Pinz\u00f3n CE, Restrepo OI. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017. doi: https:\/\/doi.org\/10.1080\/13697137.2017.1329291","DOI":"10.1080\/13697137.2017.1329291"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hirschberg AL, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55-61. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2021.04.005","DOI":"10.1016\/j.maturitas.2021.04.005"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339-360. doi: https:\/\/doi.org\/10.1097\/GME.0000000000001468","DOI":"10.1097\/GME.0000000000001468"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Shlyakhto EV, Sukhikh GT, Serov VN, Dedov II, Arutyunov GP, et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Problems of Endocrinology. 2023;69(5):115-136. (In Russ.). doi: https:\/\/doi.org\/10.14341\/probl13394","DOI":"10.14341\/probl13394"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13575\/10845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:51:42Z","timestamp":1747997502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,20]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13575","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}